Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, has announced it will release its second quarter 2024 financial results on Tuesday, August 13, 2024, before the market opens. The company will host a live webcast at 8am EDT on the same day to discuss the results.
Investors and interested parties can access the webcast through a registration link or via the Events & Presentations page on the company's website. A replay of the webcast will be available on Praxis' website for 90 days following the event. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and operational progress in developing treatments for CNS disorders characterized by neuronal excitation-inhibition imbalance.
Positive
- None.
Negative
- None.
News Market Reaction – PRAX
In the trading session that priced this news, PRAX gained 3.12%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the second quarter ended June 30, 2024, before the financial markets open on Tuesday, August 13, 2024.
The Company will host a live webcast the same morning at 8am EDT, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
